160 related articles for article (PubMed ID: 17227588)
1. Lentiviral-mediated gene correction of mucopolysaccharidosis type IIIA.
Anson DS; McIntyre C; Thomas B; Koldej R; Ranieri E; Roberts A; Clements PR; Dunning K; Byers S
Genet Vaccines Ther; 2007 Jan; 5():1. PubMed ID: 17227588
[TBL] [Abstract][Full Text] [Related]
2. Lentiviral-mediated gene therapy for murine mucopolysaccharidosis type IIIA.
McIntyre C; Derrick Roberts AL; Ranieri E; Clements PR; Byers S; Anson DS
Mol Genet Metab; 2008 Apr; 93(4):411-8. PubMed ID: 18248829
[TBL] [Abstract][Full Text] [Related]
3. Correction of murine mucopolysaccharidosis type IIIA central nervous system pathology by intracerebroventricular lentiviral-mediated gene delivery.
McIntyre C; Derrick-Roberts AL; Byers S; Anson DS
J Gene Med; 2014; 16(11-12):374-87. PubMed ID: 25418946
[TBL] [Abstract][Full Text] [Related]
4. Impaired neural differentiation of MPS IIIA patient induced pluripotent stem cell-derived neural progenitor cells.
Lehmann RJ; Jolly LA; Johnson BV; Lord MS; Kim HN; Saville JT; Fuller M; Byers S; Derrick-Roberts ALK
Mol Genet Metab Rep; 2021 Dec; 29():100811. PubMed ID: 34712574
[TBL] [Abstract][Full Text] [Related]
5. Improvement in behaviour after substrate deprivation therapy with rhodamine B in a mouse model of MPS IIIA.
Roberts AL; Rees MH; Klebe S; Fletcher JM; Byers S
Mol Genet Metab; 2007; 92(1-2):115-21. PubMed ID: 17681480
[TBL] [Abstract][Full Text] [Related]
6. Low-dose, continuous enzyme replacement therapy ameliorates brain pathology in the neurodegenerative lysosomal disorder mucopolysaccharidosis type IIIA.
King B; Hassiotis S; Rozaklis T; Beard H; Trim PJ; Snel MF; Hopwood JJ; Hemsley KM
J Neurochem; 2016 May; 137(3):409-22. PubMed ID: 26762778
[TBL] [Abstract][Full Text] [Related]
7. Recombinant human sulphamidase: expression, amplification, purification and characterization.
Bielicki J; Hopwood JJ; Melville EL; Anson DS
Biochem J; 1998 Jan; 329 ( Pt 1)(Pt 1):145-50. PubMed ID: 9405287
[TBL] [Abstract][Full Text] [Related]
8. Sulphamidase.
Anson DS; Bielicki J
Int J Biochem Cell Biol; 1999; 31(3-4):363-7. PubMed ID: 10224661
[TBL] [Abstract][Full Text] [Related]
9. Glycosaminoglycan levels and structure in a mucopolysaccharidosis IIIA mice and the effect of a highly secreted sulfamidase engineered to cross the blood-brain barrier.
Maccari F; Sorrentino NC; Mantovani V; Galeotti F; Fraldi A; Volpi N
Metab Brain Dis; 2017 Feb; 32(1):203-210. PubMed ID: 27585464
[TBL] [Abstract][Full Text] [Related]
10. Gastrointestinal pathology in a mouse model of mucopolysaccharidosis type IIIA.
Roberts AL; Howarth GS; Liaw WC; Moretta S; Kritas S; Lymn KA; Yazbeck R; Tran C; Fletcher JM; Butler RN; Byers S
J Cell Physiol; 2009 May; 219(2):259-64. PubMed ID: 19170061
[TBL] [Abstract][Full Text] [Related]
11. Early disease course is unaltered in mucopolysaccharidosis type IIIA (MPS IIIA) mice lacking α-synuclein.
Soe K; Beard H; Neumann D; Trim PJ; Duplock S; Snel MF; Hopwood JJ; Hemsley KM
Neuropathol Appl Neurobiol; 2019 Dec; 45(7):715-731. PubMed ID: 30907009
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of glycosaminoglycan synthesis using rhodamine B in a mouse model of mucopolysaccharidosis type IIIA.
Roberts AL; Thomas BJ; Wilkinson AS; Fletcher JM; Byers S
Pediatr Res; 2006 Sep; 60(3):309-14. PubMed ID: 16857766
[TBL] [Abstract][Full Text] [Related]
13. Correction of mucopolysaccharidosis type IIIA somatic and central nervous system pathology by lentiviral-mediated gene transfer.
McIntyre C; Byers S; Anson DS
J Gene Med; 2010 Sep; 12(9):717-28. PubMed ID: 20683858
[TBL] [Abstract][Full Text] [Related]
14. Cloning of the sulphamidase gene and identification of mutations in Sanfilippo A syndrome.
Scott HS; Blanch L; Guo XH; Freeman C; Orsborn A; Baker E; Sutherland GR; Morris CP; Hopwood JJ
Nat Genet; 1995 Dec; 11(4):465-7. PubMed ID: 7493035
[TBL] [Abstract][Full Text] [Related]
15. Exocytosis is impaired in mucopolysaccharidosis IIIA mouse chromaffin cells.
Keating DJ; Winter MA; Hemsley KM; Mackenzie KD; Teo EH; Hopwood JJ; Brooks DA; Parkinson-Lawrence EJ
Neuroscience; 2012 Dec; 227():110-8. PubMed ID: 23022219
[TBL] [Abstract][Full Text] [Related]
16. A highly secreted sulphamidase engineered to cross the blood-brain barrier corrects brain lesions of mice with mucopolysaccharidoses type IIIA.
Sorrentino NC; D'Orsi L; Sambri I; Nusco E; Monaco C; Spampanato C; Polishchuk E; Saccone P; De Leonibus E; Ballabio A; Fraldi A
EMBO Mol Med; 2013 May; 5(5):675-90. PubMed ID: 23568409
[TBL] [Abstract][Full Text] [Related]
17. Hematopoietic stem cell and gene therapy corrects primary neuropathology and behavior in mucopolysaccharidosis IIIA mice.
Langford-Smith A; Wilkinson FL; Langford-Smith KJ; Holley RJ; Sergijenko A; Howe SJ; Bennett WR; Jones SA; Wraith J; Merry CL; Wynn RF; Bigger BW
Mol Ther; 2012 Aug; 20(8):1610-21. PubMed ID: 22547151
[TBL] [Abstract][Full Text] [Related]
18. Intravenous delivery of a chemically modified sulfamidase efficiently reduces heparan sulfate storage and brain pathology in mucopolysaccharidosis IIIA mice.
Gustavsson S; Ohlin Sjöström E; Tjernberg A; Janson J; Westermark U; Andersson T; Makower Å; Arnelöf E; Andersson G; Svartengren J; Ekholm C; Svensson Gelius S
Mol Genet Metab Rep; 2019 Dec; 21():100510. PubMed ID: 31528541
[TBL] [Abstract][Full Text] [Related]
19. Sulphamidase activity in leucocytes, cultured skin fibroblasts and amniotic cells: diagnosis of the Sanfilippo A syndrome with the use of radiolabelled disaccharide substrate.
Hopwood JJ; Elliott H
Clin Sci (Lond); 1981 Dec; 61(6):729-35. PubMed ID: 6794973
[TBL] [Abstract][Full Text] [Related]
20. Effect of high dose, repeated intra-cerebrospinal fluid injection of sulphamidase on neuropathology in mucopolysaccharidosis type IIIA mice.
Mader KM; Beard H; King BM; Hopwood JJ
Genes Brain Behav; 2008 Oct; 7(7):740-53. PubMed ID: 18518922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
